Company Overview and News
Environmental Clean Technologies Ltd’s (ASX:ESI) (ECT) shares are trading about 8% higher intra-day at $0.014 after completing the basic design for the Matmor component of its planned India project.
Environmental Clean Technologies Ltd (ASX:ESI) is preparing to outline details in relation to its capital management program, and the ASX has granted the company a trading halt to prepare.
As a joint venture proposal of public sector companies, NLC Ltd and NMDC with an Australian company called Environmental Clean Technologies, has been sent to NITI Aayog for review, the Australian company has spoken to its shareholders of the need for “polite persistence”.
Environmental Clean Technologies (ASX:ESI) has been granted a trading halt by the ASX this morning, with its shares placed in pre-open.
SYDNEY, AUSTRALIA and INDIANAPOLIS, IN--(Marketwired - Dec 22, 2016) - Equities First Holdings, LLC (EFH), a provider of alternative shareholder financing, and its Australian subsidiary, Equities First Holdings (Australia) Pty Ltd (EFH/A) are pleased to announce that EFH has entered into a transaction with Environmental Clean Technologies Limited (ECT) to provide funding to be used in the development of major projects in India.
The proposed integrated Coldry-Matmor process pilot plant will enable steel production using ESI’s proprietary process of reducing moisture in lignite and purification of iron ore. The $3-5 million financing arrangement has been signed with Equities First Holdings (EFH) to fund the Indian project’s detailed design and engineering stage. This arrangement involves qualifying investors entering into funding facilities with EFH for the sole purpose of financing their ESI options conversions at an interest rate of 5.
The activities at the test facility are linked to preparations for a demonstration plant in India.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...